448 related articles for article (PubMed ID: 12948019)
21. The impact of protein on Caco-2 permeability of low mass balance compounds for absorption projection and efflux substrate identification.
Liu T; Chang LJ; Uss A; Chu I; Morrison RA; Wang L; Prelusky D; Cheng KC; Li C
J Pharm Biomed Anal; 2010 Apr; 51(5):1069-77. PubMed ID: 20036089
[TBL] [Abstract][Full Text] [Related]
22. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.
Saitoh H; Aungst BJ
Pharm Res; 1995 Sep; 12(9):1304-10. PubMed ID: 8570526
[TBL] [Abstract][Full Text] [Related]
23. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.
Shirasaka Y; Sakane T; Yamashita S
J Pharm Sci; 2008 Jan; 97(1):553-65. PubMed ID: 17828734
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro.
Kim WY; Benet LZ
Pharm Res; 2004 Jul; 21(7):1284-93. PubMed ID: 15290871
[TBL] [Abstract][Full Text] [Related]
25. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of an immortalized retinal endothelial cell line as an in vitro model for drug transport studies across the blood-retinal barrier.
Shen J; Cross ST; Tang-Liu DD; Welty DF
Pharm Res; 2003 Sep; 20(9):1357-63. PubMed ID: 14567628
[TBL] [Abstract][Full Text] [Related]
27. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
28. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Zhang Y; Huang J; Liu Y; Guo T; Wang L
Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
[TBL] [Abstract][Full Text] [Related]
29. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells.
Balimane PV; Chong S; Patel K; Quan Y; Timoszyk J; Han YH; Wang B; Vig B; Faria TN
Arch Pharm Res; 2007 Apr; 30(4):507-18. PubMed ID: 17489369
[TBL] [Abstract][Full Text] [Related]
30. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone.
Wu SJ; Robinson JR
Pharm Res; 1999 Aug; 16(8):1266-72. PubMed ID: 10468030
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
[TBL] [Abstract][Full Text] [Related]
32. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Dec; 94(12):2632-43. PubMed ID: 16258992
[TBL] [Abstract][Full Text] [Related]
33. Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical models.
Riede J; Umehara KI; Schweigler P; Huth F; Schiller H; Camenisch G; Poller B
Eur J Pharm Sci; 2019 Apr; 132():132-141. PubMed ID: 30857914
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
35. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
Shirasaka Y; Kawasaki M; Sakane T; Omatsu H; Moriya Y; Nakamura T; Sakaeda T; Okumura K; Langguth P; Yamashita S
Drug Metab Pharmacokinet; 2006 Oct; 21(5):414-23. PubMed ID: 17072095
[TBL] [Abstract][Full Text] [Related]
36. Cellular Uptake and Transport Characteristics of FL118 Derivatives in Caco-2 Cell Monolayers.
Zhou Y; Hu W; Zhang X; Wang Y; Zhuang W; Li F; Li Q
Chem Pharm Bull (Tokyo); 2021; 69(11):1054-1060. PubMed ID: 34719586
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
Wang Q; Rager JD; Weinstein K; Kardos PS; Dobson GL; Li J; Hidalgo IJ
Int J Pharm; 2005 Jan; 288(2):349-59. PubMed ID: 15620875
[TBL] [Abstract][Full Text] [Related]
38. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
39. Drug exsorption from blood into the gastrointestinal tract.
Arimori K; Nakano M
Pharm Res; 1998 Mar; 15(3):371-6. PubMed ID: 9563065
[TBL] [Abstract][Full Text] [Related]
40. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers.
Hosoya KI; Kim KJ; Lee VH
Pharm Res; 1996 Jun; 13(6):885-90. PubMed ID: 8792427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
